Clinical Trials Logo

Drug-Induced Liver Injury clinical trials

View clinical trials related to Drug-Induced Liver Injury.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05532345 Completed - Clinical trials for Autoimmune Hepatitis

Discrimination of DILI and AIH by Artificial Intelligence

Start date: July 1, 2022
Phase:
Study type: Observational

A retrospective, multi-center, non-interventional cohort study has been going to explore whether artificial intelligence can discriminate Drug-induced liver injury and Autoimmune hepatitis. A machine learning-based tool will be developed and validated to help clinicians to differentiate between Drug-induced liver injury and Autoimmune hepatitis

NCT ID: NCT03665402 Completed - Tuberculosis Clinical Trials

A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status

Start date: May 13, 2018
Phase: N/A
Study type: Interventional

A clinical trial to investigate the appropriate dose of isoniazid according to NAT2 polymorphism status in Korean subjects

NCT ID: NCT03602703 Completed - Clinical trials for Drug-Induced Liver Injury

Immune Responses in Hepatocellular Carcinoma Patients After Treatment With Direct Acting Antiviral Drugs

Start date: July 1, 2018
Phase:
Study type: Observational

Case control Study to assess the difference of immune cell responses between patients with chronic HCV- related liver cirrhosis who develop HCC after treatment with DAAs and those who do not develop HCC

NCT ID: NCT03211208 Completed - Tuberculosis Clinical Trials

Assessing Antibiotic Induced Liver Injury for Stratification of Tuberculosis Patients

ALISTER
Start date: May 22, 2017
Phase:
Study type: Observational

A panel of highly sensitive circulating biomarkers for acute liver injury have been identified and demonstrated to identify liver injury on first presentation to hospital before standard tests are elevated in patients with paracetamol overdose. The investigators wish to test these biomarkers in patients with active and latent tuberculosis to see if they can be used to stratify patients undertaking anti-tuberculosis drug therapy. Anti-tuberculosis drug induced liver injury is the most frequent side-effect of anti-tuberculosis therapy, affecting 2-5% of tuberculosis patients seen at the Royal Infirmary Edinburgh and hindering their effective treatment. Patients will be recruited from the TB out-patient clinic at the Royal Infirmary Edinburgh. Blood samples will be taken every time the patient visits the clinic and also retrieved from the biochemistry lab. The biomarkers in the blood samples will be analysed to determine if they rise in patients who develop liver injury.

NCT ID: NCT03092817 Completed - HIV Clinical Trials

Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial)

Start date: May 25, 2017
Phase: Phase 3
Study type: Interventional

The investigators will conduct a randomized, double blind, placebo controlled trial of adjunctive dexamethasone in the initial (6-8 weeks) treatment of tuberculous meningitis in Vietnamese adults. The trial will address a primary hypothesis in all enrolled patients, and a secondary hypothesis in a sub-group of enrolled patients who develop anti-tuberculosis drug-induced liver injury (DILI). The primary hypothesis is adjunctive dexamethasone increases survival from TBM in HIV co-infected adults. The secondary hypothesis is current guidelines for the management of anti-tuberculosis drug-induced liver injury in those with TBM result in the premature interruption of rifampicin and isoniazid (the critical active drugs in early therapy) and are thereby placing participants at risk of poor outcomes.

NCT ID: NCT02734966 Completed - Clinical trials for Drug-Induced Liver Injury

Efficacy and Safety Study of Magnesium Isoglycyrrhizinate Injection in Subjects With Acute Drug-induced Liver Injury

Start date: December 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the safety, effective dosage and treatment of Magnesium Isolycyrrhizinate Injection to cure the acute drug-induced liver injury compared with the Tiopronin Injection.

NCT ID: NCT02431832 Completed - Healthy Clinical Trials

Exploration of microRNA and Metabolomics Biomarkers Predicting Drug Induced Liver Injury in Elderly People

Start date: February 2015
Phase: Phase 1
Study type: Interventional

An open-label, one-sequence, multiple administration study for exploration of microRNA and metabolomics biomarkers to predict drug induced liver injury in healthy elderly Korean people.

NCT ID: NCT02407964 Completed - Clinical trials for Drug-Induced Liver Injury

A Retrospective Study on Drug Induced Liver Injury in China

DILI-R
Start date: March 2015
Phase: N/A
Study type: Observational

This is a multi-center, open-enrollment, retrospective, non-interventional epidemiologic study without any clinical treatment. Its primary objective is to understand 1) incidence of drug-induced liver injury, including incidences among all the hospitalized patient, among patients in department of hepatic diseases, digestive diseases, oncology, hematology etc., individually; 2) epidemiologic characteristics of drug-induced liver injury, including suspected medications, clinical types, histological characteristics, severity and outcomes.

NCT ID: NCT02299739 Completed - Clinical trials for Musculoskeletal Diseases

Liver Enzyme Abnormalities and Risk Factors in Taking Herbal Medicine

Start date: December 2005
Phase:
Study type: Observational

Herb-induced liver injury is an important issue in musculoskeletal diseases where herbal medicine is most frequently used. The low prevalence of drug-induced liver injury (DILI) gives rise to the need for large-scale patient studies. We assessed the prevalence of liver injury of 6,894 musculoskeletal disease inpatients taking herbal medicine.

NCT ID: NCT02182167 Completed - Clinical trials for Drug-Induced Liver Injury

A Trial Of Intravenous N-Acetylcysteine In The Management Of Antituberculous Drug-Induced Hepatitis

NAC in TB DIH
Start date: May 2014
Phase: Phase 2/Phase 3
Study type: Interventional

We will conduct a randomized placebo controlled trial to determine whether administration of intravenous (IV) NAC to participants with TB DIH, in dosages similar to that used in paracetamol poisoning, can improve recovery from hepatotoxicity.